Author:
Jaber Waed,Abdaljalil Ammar,Ali Aya,Abu Haleeqa Mohamed,Mheidly Kayane
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Progress and paradigms in multiple myeloma;Anderson KC;Clin Cancer Res,2016
2. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study;Moreau P;Lancet,2019
3. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy;Gandhi UH;Leukemia,2019
4. Belantamab mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety;Offidani M;Drug Des Devel Ther,2021
5. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM- 2): a two-arm, randomised, open-label, phase 2 study;Lonial S;Lancet Oncol,2020